Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
Rosuvastatin . calcium salt
30
CHF
CHF 30.00
In stock
AG-CR1-3728-M01010 mgCHF 30.00
AG-CR1-3728-M05050 mgCHF 60.00
AG-CR1-3728-M250250 mgCHF 220.00
| Product Details | |
|---|---|
| Synonyms | Crestor |
| Product Type | Chemical |
| Properties | |
| Formula |
C22H27FN3O6S . 1/2Ca |
| MW | 480.6 . 20.0 |
| CAS | 147098-20-2 |
| RTECS | MJ9675070 |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white solid. |
| Solubility | Soluble in DMSO (20mg/ml) or DMF (20mg/ml). |
| Identity | Determined by 1H-NMR. |
| InChi Key | VGAZDTHGPVFCCO-YFRSHGDPSA-K |
| Smiles | CN(S(C)(=O)=O)C1=NC(C2=CC=C(F)C=C2)=C(/C=C/[C@H](C[C@@H](O)CC([O-])=O)O)C(C(C)C)=N1.[Ca+2] |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Keep cool and dry. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
- Rosuvastatin is a potent competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the statin class of cholesterol-lowering drugs.
- Rosuvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. Formulations containing rosuvastatin reduce low-density lipoprotein (LDL) and C-reactive protein and increase high-density lipoprotein (HDL) in humans.
- Shown to have anti-inflammatory, antioxidant, antithrombotic and insulin sensitizing properties.
- Identified as a potential inhibitor of SARS-CoV-2, responsible for COVID-19.
Product References
- Structural mechanism for statin inhibition of HMG-CoA reductase: E.S. Istvan & J. Deisenhofer; Science 292, 1160 (2001)
- Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: F. McTaggart, et al.; Am. J. Cardiol. 87, 28B (2001)
- Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor: A.G. Olsson, et al.; Cardiovasc. Drug Rev. 20, 303 (2002) (Review)
- Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors: J.A. Tobert; Nat. Rev. Drug Discov. 2, 517 (2003) (Review)
- Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia: A. Cheng-Lai; Heart Dis. 5, 72 (2003) (Review)
- Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin: G.A. Holdgate, et al.; Biochem. Soc. Trans. 31, 528 (2003) (Review)
- Rosuvastatin: a review of its effect on atherosclerosis: G.M. Keating & D.M. Robinson; Am. J. Cardiovasc. Drugs. 8, 127 (2008) (Review)
- Rosuvastatin: Beyond the cholesterol-lowering effect: F. Cortese, et al.; Pharmacol. Res. 107, 1 (2016) (Review)
- Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning: P. Wang, et al.; ChemRxiv (Preprint) (2020)
Related Products
